Safety and precautions for use of Roprostim (Huierning) in special populations

Romiplostim () is a recombinant human thrombopoietin receptor agonist (TPO-RA), which increases platelet production by promoting the proliferation and maturation of bone marrow megakaryocytes. This drug is mainly used to treat chronic immune thrombocytopenia (ITP), especially in patients who have an inadequate response to glucocorticoids, immune globulin, or splenectomy. Although the efficacy and rapid onset of action of Roprostim are accurate, the safety of medication in special groups requires special attention to ensure the balance between efficacy and risks.

For elderly patients, Roprostim is generally well tolerated, but attention should be paid to liver and kidney function and cardiovascular status. As the elderly have reduced metabolic function and take more concomitant medications, the risk of drug-drug interactions increases. Some patients may develop thrombotic events after elevated platelets, especially those with a history of hypertension, diabetes, or atherosclerosis. Therefore, platelet levels should be monitored regularly during treatment to avoid excessive elevation (>400×10⁹/L), and the dose should be adjusted or the drug temporarily discontinued if necessary.

For patients with abnormal liver and kidney function, loprostim should be used with caution. Although drugs are primarily cleared through the reticuloendothelial system, hepatic insufficiency may affect their metabolism, thereby increasing the risk of adverse reactions. Patients with mild to moderate liver function impairment can use it under the guidance of a doctor, and closely monitor transaminase levels and bilirubin changes; if obvious liver damage or jaundice occurs, the drug should be discontinued immediately. There is currently a lack of sufficient clinical data for patients with renal insufficiency. Individualized medication should be taken after weighing the pros and cons, and changes in serum creatinine and electrolytes should be monitored.

Roprostim should be used with extreme caution in pregnant women, lactating women and children. Animal experiments suggest that it may cause potential risks to the fetus, so pregnant women should only use it when the benefits clearly outweigh the risks. Women of childbearing age should take effective contraceptive measures while taking the drug, and lactating women are advised to suspend breastfeeding to prevent the drug from being excreted through breast milk. Although a small number of clinical studies have shown good efficacy in pediatric patients, it still needs to be used under strict supervision, and the dosage needs to be accurately calculated based on body weight. Generally speaking, the principle of individualization should be adhered to when using Roprostim in special groups, and blood images and adverse reactions should be closely monitored to achieve safe and effective treatment goals.

Reference materials:https://www.drugs.com/